98818-42-9

Basic information

• Product Name: (3S,5S)-3-benzyl-5-{(1S)-1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}dihydrofuran-2-(3H)-one
• Synonyms: (3S,5S)-3-benzyl-5-{(1S)-1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}dihydrofuran-2-(3H)-one
• CAS NO: 98818-42-9
• Molecular Weight: 395.499
• Mol File: 98818-42-9.mol

Chemical Properties

• CAS DataBase Reference: (3S,5S)-3-benzyl-5-{(1S)-1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}dihydrofuran-2-(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,5S)-3-benzyl-5-{(1S)-1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}dihydrofuran-2-(3H)-one(98818-42-9)
• EPA Substance Registry System: (3S,5S)-3-benzyl-5-{(1S)-1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}dihydrofuran-2-(3H)-one(98818-42-9)

Safety Data

• Hazardous Substances Data: 98818-42-9(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 133333-27-4 tert-butyl (1S)-1-[(2S)-5-oxotetrahydrofuran-2-yl]-2-phenylethylcarbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 146500-14-3 [(S)-1-((S)-4-Benzyl-5-oxo-2,5-dihydro-furan-2-yl)-2-phenyl-ethyl]-carbamic acid tert-butyl ester 
• 620-05-3 iodomethylbenzene 
• 591-51-5 phenyllithium 
• 104293-40-5 (5S,1'S)-5-<1-<<(tert-butyloxy)carbonyl>amino>-2-phenylethyl>-3-methylenedihydrofuran-2(4H)-one 
• 14131-84-1 2,3:5,6-di-O-isopropylidene-α-D-mannofuranose 
• 61845-17-8 methyl D-2,3-dideoxyglucofuranoside 
• 137007-28-4 (S)-2-Methoxy-5-(R)-oxiranyl-tetrahydro-furan 
• 68144-11-6 1,4-anhydro-2-deoxy-5,6-O-isopropylidene-D-arabinohex-1-enitol 
• 530-26-7 D-Mannose 
• 98818-41-8 (3R,5S)-3-benzyl-5-{(1S)-1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}dihydrofuran-2-(3H)-one 
• 207222-80-8 (Z)-(S)-2-Benzyl-5-tert-butoxycarbonylamino-4-oxo-6-phenyl-hex-2-enoic acid methyl ester 

Downstream Products

• 98818-44-1 (2S,4S,5S)-2-Benzyl-5-tert-butoxycarbonylamino-4-hydroxy-6-phenyl-hexanoic acid 
• 98818-41-8 (3R,5S)-3-benzyl-5-{(1S)-1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}dihydrofuran-2-(3H)-one 
• 144141-82-2 (2S,4S,5S)-2,5-bis<<(1,1-dimethylethoxy)carbonyl>amino>-1,6-diphenyl-4-hydroxyhexane 
• 146500-06-3 (2S,4S,5S)-2-<<(phenylmethoxy)carbonyl>amino>-4-<<(1,1-dimethylethyl)dimethylsilyl>oxy>-5-<<(1,1-dimethylethoxy)carbonyl>amino>-1,6-diphenylhexane 
• 146500-09-6 (2S,4S,5S)-2-<<(phenylmethoxy)carbonyl>amino>-5-<<(1,1-dimethylethoxy)carbonyl>amino>-1,6-diphenyl-4-hydroxyhexane 
• 144164-55-6 di(tert-butyl) N,N'-((2S,5S)-3-oxo-1,6-diphenylhexane-2,5-diyl)dicarbamate 
• 146500-15-4 ((1S,3S,4S)-4-Amino-1-benzyl-3-hydroxy-5-phenyl-pentyl)-carbamic acid benzyl ester 
• 144163-88-2 ((1S,2S,4S)-4-amino-1-benzyl-2-hydroxy-5-phenyl-pentyl)-carbamic acid tert-butyl ester 
• 98818-50-9 (2S,4S,5S)-5-{[(1,1-dimethylethoxy)carbonyl]amino}-4-{[(1,1-dimethylethyl)dimethylsilyl]oxy}-6-phenyl-2-(phenylmethyl)hexanoic acid 
• 147912-04-7 [(1S,2S,4R)-1-Benzyl-2-(tert-butyl-dimethyl-silanyloxy)-4-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-5-phenyl-pentyl]-carbamic acid tert-butyl ester 
• 126456-36-8 L-685434 
• 126410-32-0 {(1S,2S,4R)-1-Benzyl-2-(tert-butyl-dimethyl-silanyloxy)-4-[(S)-1-((S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-5-phenyl-pentyl}-carbamic acid tert-butyl ester 
• 126409-24-3 {(1S)-benzyl-(4R)-[1-((1S)-carbamoyl-2-phenyl-ethylcarbamoyl)-(1S)-3-methyl-butyl-carbamoyl]-(2S)-hydroxy-5-phenyl-pentyl} carbamic acid tert-butyl ester 
• 98818-48-5 C₃₆H₅₉NO₅Si₂ 

Relevant articles and documents

Application of the asymmetric aminohydroxylation reaction for the syntheses of HIV-protease inhibitor, hydroxyethylene dipeptide isostere and γ-amino acid derivative

An enantioselective synthesis of lactone 1, a precursor to the (2R,4S,5S) hydroxyethylene dipeptide isostere and amino acid AHPPA 2 has been accomplished from the common intermediate 5 employing Sharpless asymmetric aminohydroxylation as the key step.

Allyltrichlorostannane additions to α-amino aldehydes: Application to the total synthesis of the aspartyl protease inhibitors L-682,679, L-684,414, L-685,434, and L-685,458

The hydroxyethylene dipeptide isosteres L-682,679, L-684,414, L-685,434, and L-685,458 were synthesized in a few steps by a sequence involving an allyltrichlorostannane coupling with an α-amino aldehyde, followed by hydroboration of the corresponding 1,2-

Short total synthesis of aspartyl protease inhibitors L-685,434, L-682,679 and L-685,458

Hydroxyethylene dipeptide isosteres L-685,434, L-682,679 and L-685,458 were synthesized in a few steps by a sequence involving an allyltrichlorostannane coupling with an α-aminoaldehyde followed by hydroboration of the corresponding 1,2-syn and 1,2-anti a

Peptide inhibitors of aspartic proteinases with hydroxyethylene isostere replacement of peptide bond. I. Preparation of four diastereoisomeric (2R or 2S, 4R or 4S, 5S)-2-benzyl-5-[(tert-butoxycarbonyl)amino]-4-hydroxy-6-phenylhexanoic acids

By two separate routes were prepared four diastereoisomers of (2R or 2S,5R or 5S)-3-benzyl-5-{(1S)-[(tert-butoxycarbonyl)amino]-2-phenylethyl}tetrahydrofuran- 2-ones (11, 12, 17 and 18). Since the furanones were derived from (S)-phenylalanine, absolute co

5-amino-4-hydroxyhexanoic acid derivatives

Compounds of formula I STR1 or their hydroxy-protected derivatives, and compounds of formula I' STR2 wherein T is an acyl radical of formula Z STR3 wherein Rz is unsubstituted or substituted hydrocarbyl wherein at least one carbon atom has been replaced by a hetero atom with the proviso that a hetero atom is not bonded directly to the carbonyl to which the radical Rz is bonded, alkyl having two or more carbon atoms, lower alkenyl, lower alkynyl, aryl or unsubstituted or substituted amino, and wherein the radicals R1, B1, R2, R3, A1, A2 and NR4 R5 are as defined in the description, and precursors thereof, are described. The compounds have pharmaceutical activity, for example in the treatment of retroviral diseases, such as AIDS.

Use of compositions for combating tumour diseases

The present invention relates to the use of inhibitors of HIV aspartate proteases, such as HIV-1- or HIV-2-protease, and their salts and to prodrugs for inhibiting the growth of tumors, especially those tumors which do not respond to the inhibition of HIV

Potent HIV-1 Protease Inhibitors: Stereoselective Synthesis of a Dipeptide Mimic

The synthesis of a differentially protected dipeptide mimic 10 in enantiomerically pure form is described.The key step involves the epimerization of the C-2 center of the lactone 4, hydrolysis and protection of the resulting hydroxy acid, followed by Curt

Dipeptide Isosteres. 2. Synthesis of Hydroxyethylene Dipeptide Isostere Diastereomers From a Common γ-Lactone Intermediate. Preparation of Renin and HIV-1 Protease Inhibitor Transition State Mimics.

A general strategy for the synthesis of the hydroxyethylene dipeptide isostere diastereomers C or D has been developed.The syntheses proceeded through a common γ-lactone intermediate A or B.The C(3α)γ-lactone diastereomer A was prepared from the N-Cbz pro

An Efficient Synthesis of Hydroxyethylene Dipeptide Isosteres: The Core Unit of Potent HIV-1 Protease Inhibitors

An efficient and stereocontrolled synthesis of hydroxyethylene dipeptide isosteres 1 from commercially available, optically pure D-mannose is described.This synthesis represents a practical and enantioselective entry to a range of other dipeptide isostere